PBAC's latest decision on Cetrorelix: Recommended (2025). Considered for Prevention of premature luteinisation and ovulation in patients undergoing controlled ovarian stimulation followed by oocyte pick up and assisted reproductive techniques.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Patients undergoing controlled ovarian stimulation for assisted reproductive technology, receiving medical services as described in MBS items 13200, 13201, 13202 or 13203
Therapy area
Women's health
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
cetrorelix (Cetrotide)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as equi-effective doses assumed